What is the 13F Pro Quality Score for OCUL?

13F Pro ranks OCULAR THERAPEUTIX, INC (OCUL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OCUL's current score at https://13fpro.ai/research/OCUL (free sign-up required for the full ranking).

Which hedge funds own the most OCUL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of OCUL include FMR, Deep Track Capital,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/OCUL as soon as new 13F filings post.

Where does 13F Pro source OCUL data?

All OCULAR THERAPEUTIX, INC fundamentals and ownership data come directly from SEC EDGAR. OCULAR THERAPEUTIX, INC files with the SEC under CIK 1393434. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OCUL in?

OCULAR THERAPEUTIX, INC (OCUL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OCUL research updated on 13F Pro?

OCUL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

OCULAR THERAPEUTIX, INC(OCUL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1393434 OCUL stock profile & AI dashboard →

13F Pro Quality Score

12.8/100

Rank #2,776 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

14.8/100

Profitability

3.2/100

Balance Sheet

6.0/100

Earnings Quality

30.0/100

Free Cash Flow

3.3/100

Institutional Flow

90.1/100

Revenue Scale

11.0/100

Dilution Risk

3.5/100

OCUL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for OCULAR THERAPEUTIX, INC (OCUL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OCUL at 12.8/100 on a 32-signal composite quality model, placing it at rank #2,776 of 2,879 stocks — the bottom half of the AI-ranked universe. OCUL scores in the top quartile across institutional flow (90.1). Areas of concern include profitability (3.2) and free cash flow (3.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), OCULAR THERAPEUTIX, INC reports quarterly revenue of $10.8M, net income of $-88.6M, free cash flow of $-70.7M. Top institutional holders of OCUL by reported 13-F value include FMR, Deep Track Capital,, BlackRock,, based on the most recent SEC filings. OCUL trades on the Nasdaq exchange and files with the SEC under CIK 1393434. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OCUL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OCULAR THERAPEUTIX, INC directly from SEC EDGAR. OCULAR THERAPEUTIX, INC's 13F Pro composite quality score has ranged between 8 and 48 since 2021, currently 12.8 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about OCULAR THERAPEUTIX, INC

Quirks, history, and lore behind OCUL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the low tens of millions of dollars, with most of it driven by a single commercial product — the classic biotech bet-everything-on-one-drug model.
3
The History
Founded in the early 2000s, the company built its entire platform around a proprietary hydrogel drug-delivery technology designed to release medicine slowly and precisely at a target site.
4
The Secret
The secret weapon is a biodegradable, water-swelling gel that doubles as both the drug depot and the implant — no removal procedure required, because it dissolves on its own.
5
The Lore
Its lead approved product, Dextenza, is a tiny sustained-release insert placed inside the lower eyelid after eye surgery to deliver steroids without daily drops — patients love not having to remember anything.
6
The Giveaway
The name is basically a spoiler: it's a company laser-focused on ocular drug delivery, with a pipeline of eye-drop-killing implants for conditions from post-op inflammation to dry eye disease.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$10.8M

Net Income

Q1 2026

$-88.6M

Free Cash Flow

Q1 2026

$-70.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-18.5% YoY

$52.0MFY 2025

FY22 $51.5MFY23 $58.4MFY24 $63.7MFY25 $52.0M

Net Income

-37.4% YoY

$-265.9MFY 2025

FY22 $-71.0MFY23 $-80.7MFY24 $-193.5MFY25 $-265.9M

Operating Income

-57.2% YoY

$-270.0MFY 2025

FY22 $-78.7MFY23 $-82.4MFY24 $-171.8MFY25 $-270.0M

EPS (Diluted)

-16.4% YoY

$-1.42FY 2025

FY22 $-0.97FY23 $-1.02FY24 $-1.22FY25 $-1.42

Total Assets

+76.5% YoY

$808.1MFY 2025

FY22 $149.3MFY23 $252.1MFY24 $457.9MFY25 $808.1M

Op. Cash Flow

-52.1% YoY

$-204.9MFY 2025

FY22 $-59.6MFY23 $-70.2MFY24 $-134.7MFY25 $-204.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$52.0M -18.5%	$63.7M +9.0%	$58.4M +13.5%	$51.5M +195.9%	$17.4M +311.7%	$4.2M
Net Income	$-265.9M -37.4%	$-193.5M -139.7%	$-80.7M -13.7%	$-71.0M +54.4%	$-155.6M -80.2%	$-86.4M
Operating Income	$-270.0M -57.2%	$-171.8M -108.5%	$-82.4M -4.7%	$-78.7M -25.2%	$-62.8M +26.8%	$-85.8M
EPS (Diluted)	$-1.42 -16.4%	$-1.22 -19.6%	$-1.02 -5.2%	$-0.97 +62.1%	$-2.56 -34.0%	$-1.91
Total Assets	$808.1M +76.5%	$457.9M +81.7%	$252.1M +68.8%	$149.3M -43.0%	$261.9M +232.6%	$78.7M
Operating Cash Flow	$-204.9M -52.1%	$-134.7M -91.8%	$-70.2M -17.8%	$-59.6M -11.3%	$-53.6M +31.0%	$-77.6M

Get alerted when OCUL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for OCULAR THERAPEUTIX, INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OCUL

FMR LLC
$276.6M32,653,764 sh
Deep Track Capital, LP
$166.7M19,686,282 sh
BlackRock, Inc.
$136.6M16,132,931 sh
Avoro Capital Advisors LLC
$104.3M12,315,000 sh
SUMMER ROAD LLC
$100.6M11,879,825 sh
VR Adviser, LLC
$87.6M10,346,926 sh
VANGUARD CAPITAL MANAGEMENT LLC
$73.9M8,719,039 sh
ALLIANCEBERNSTEIN L.P.
$50.1M4,129,687 sh
Point72 Asset Management, L.P.
$46.9M5,534,985 sh
STATE STREET CORP
$39.9M4,708,419 sh

Fund	Value	Shares
FMR LLC	$276.6M	32,653,764
Deep Track Capital, LP	$166.7M	19,686,282
BlackRock, Inc.	$136.6M	16,132,931
Avoro Capital Advisors LLC	$104.3M	12,315,000
SUMMER ROAD LLC	$100.6M	11,879,825
VR Adviser, LLC	$87.6M	10,346,926
VANGUARD CAPITAL MANAGEMENT LLC	$73.9M	8,719,039
ALLIANCEBERNSTEIN L.P.	$50.1M	4,129,687
Point72 Asset Management, L.P.	$46.9M	5,534,985
STATE STREET CORP	$39.9M	4,708,419

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OCUL on your watchlist

Track score changes the day OCULAR THERAPEUTIX, INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OCUL a good stock to buy?

13F Pro's AI-powered analysis of OCULAR THERAPEUTIX, INC (OCUL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OCUL are available on the OCUL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OCUL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OCUL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of OCULAR THERAPEUTIX, INC's investment landscape.